Completed PHASE4 INTERVENTIONAL NCT00185068

An Examination of the Safety and Blood Pressure Lowering Effect of Increasing Doses of Benicar® and Benicar® HCT in Patients With Hypertension

A Prospective, Open Label, Titration Study to Assess the Efficacy and Safety of Benicar® and Benicar ®HCT in Patients With Stage II Systolic Hypertension

Sponsor: Daiichi Sankyo

Conditions Hypertension

Interventions Hydrochlorothiazide Olmesartan medoxomil Olmesartan medoxomil/hydrochlorothiazide

Updated 7 times since 2017 Last updated: Sep 9, 2005 Started: Mar 31, 2004 Completion: Oct 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Hypertension, this trial is completed. The trial is conducted by Daiichi Sankyo and has accumulated 7 data snapshots since 2004. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Mar 2024 — Jul 2024 [monthly]

Completed PHASE4
Jan 2021 — Mar 2024 [monthly]

Completed PHASE4

▶ Show 2 earlier versions

Sep 2017 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Sep 2017 [monthly]

Completed PHASE4

First recorded

Mar 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Daiichi Sankyo

Data source: Daiichi Sankyo

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Auburn, United States , Buffalo, United States , DeLand, United States , Fort Lauderdale, United States , Long Beach, United States , Madison, United States , New Orleans, United States , Oklahoma City, United States , Omaha, United States , Orland Park, United States and 6 more locations